WILMINGTON, Del., March 30, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of DS Healthcare Group, Inc. (NASDAQ:DSKX)?
- Did you purchase your shares between August 13, 2015 and March 23, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the Southern District of Florida on behalf of all persons or entities that purchased the common stock of DS Healthcare Group, Inc. (“DS Healthcare” or the “Company”) (NASDAQ:DSKX) between August 13, 2015 and March 23, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased shares of DS Healthcare during the Class Period, or purchased shares prior to the Class Period and still hold DS Healthcare, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/ds-healthcare-group-inc-dskx.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on March 23, 2016 after the market closed, Defendant DS Healthcare filed a Form 8-K (the “Form 8-K”) with the SEC which disclosed errors in its unaudited condensed consolidated financial statements for the two fiscal quarters ended June 30, 2015 and September 30, 2015 and stated these financial statements should no longer be relied upon. Defendant DS Healthcare further stated that it will restate the financial statements for two fiscal quarters ended June 30, 2015 and September 30, 2015, and that the adjustments will be material to investors when finalized. These errors related to revenue recognition for certain customers and certain equity transactions. Additionally, Defendant DS Healthcare disclosed that its Board of Directors terminated Defendant Khesin as its President for cause and removed him as its Chairman of the Board for cause.
On this news, shares of DS Healthcare dropped over 35%, closing at $0.86 per share on March 24, 2016, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than May 31, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com


ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Italy Fines Apple €98.6 Million Over App Store Dominance
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



